Full Title: Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA with Osteosarcoma (CabOSTar)
Status: Active, Recruiting
Age Range: 5 - 30 years old
Locations:
- University College London Hospital, London
- Cambridge University Hospital NHS Trust, Cambridge
- Birmingham Children's Hospital, Birmingham
- Royal Victoria Infirmary, Newcastle Upon Tyne
- Christie NHS Foundation Trust, Manchester
- NHS greater Glasgow and Clyde, Glasgow
Registry Number: NCT06341712
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery.
Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid.
Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young adults.
In this study, participants will receive either cabozantinib and best supportive care or the best supportive care alone. Best supportive care will be provided at the investigator's discretion and according to institutional guidelines.
Cabozantinib will be taken by mouth (orally), as a tablet, once a day. Cabozantinib will be provided to participants who tolerate it for as long as their disease does not progress. Participants in the study receiving best supportive care alone may switch to treatment with cabozantinib and best supportive care if their disease progresses and if other eligibility criteria are met.
If you would like any more information on clinical trials in general, please contact us at The Bone Cancer Research Trust. For more information on this trial and to understand if you are eligible, please talk to your clinical team.
Donate now (This link opens in a new window) More about Osteosarcoma